Radioactive drug trial offers new hope for advanced prostate cancer
NCT ID NCT07381582
Summary
This early-stage study is testing a new radioactive drug called 161Tb-LNC1011 in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to find a safe dose, see how the drug travels in the body, and look for early signs that it might help control the cancer. Fifteen participants will receive the drug by IV, starting with a low dose that may be increased if it is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Mianyang Central Hospital
Mianyang, Sichuan, China
Contact Phone: •••-•••-••••
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.